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Abstract
AIM
To assess dietary myo-inositol in reducing stem cell 
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activation in colitis, and validate pβ-cateninS552 as a 
biomarker of recurrent dysplasia.
METHODS
We examined the effects of dietary myo-inositol 
treatment on inflammation, pβ-cateninS552 and pAkt 
levels by histology and western blot in IL-10-/- and 
dextran sodium sulfate-treated colitic mice. Additionally, 
we assessed nuclear pβ-cateninS552 in patients treated 
with myo-inositol in a clinical trial, and in patients with 
and without a history of colitis-induced dysplasia.
RESULTS
In mice, pβ-cateninS552 staining faithfully reported the 
effects of myo-inositol in reducing inflammation and 
intestinal stem cell activation. In a pilot clinical trial of 
myo-inositol administration in patients with a history of 
low grade dysplasia (LGD), two patients had reduced 
numbers of intestinal stem cell activation compared to 
the placebo control patient. In humans, pβ-cateninS552 
staining discriminated ulcerative colitis patients with a 
history of LGD from those with benign disease.
CONCLUSION
Enumerating crypts with increased numbers of pβ-
cateninS552 - positive cells can be utilized as a biomarker 
in colitis-associated cancer chemoprevention trials.
Key words: Chemoprevention; Dysplasia; Biomarker; 
Stem cell; Colitis-associated cancer
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We report that dietary myo-inositol reduced 
inflammation and intestinal stem cell activation in both 
genetic and chemically-induced mouse models of colitis. 
In a limited clinical trial of colitis patients with a history 
of recurrent low grade dysplasia (LGD), myo-inositol 
reduced the number of intestinal crypts with activated 
stem cells. This study demonstrated for the first time 
that nuclear pβ-cateninS552 staining discriminates 
between patients with inflammation and those with a 
history of LGD, suggesting that nuclear pβ-cateninS552 
staining may reflect local expansions of activated stem 
cells with neoplastic potential. Based on these data, we 
propose a more extensive clinical trial.
Bradford EM, Thompson CA, Goretsky T, Yang GY, Rodriguez 
LM, Li L, Barrett TA. Myo-inositol reduces β-catenin activation 
in colitis. World J Gastroenterol 2017; 23(28): 5115-5126 
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INTRODUCTION
Chronic inflammation in ulcerative colitis (UC) and 
Crohn’s disease (CD) contributes to an elevated risk 
of colitis-associated cancer (CAC)[1,2]. Patients with 
UC have an overall 11-fold relative risk of cancer and 
a 38-fold increased risk if they are diagnosed before 
age 30[1]. Similarly, patients with CD have an 18-fold 
increased risk of developing colorectal cancer[2]. In 
these diseases, chronic inflammation increases the 
risk of dysplasia through a variety of mechanisms. 
Oxidative stress, eicosanoid production and signaling 
through the cyclooxygenase/lipoxygenase pathways[3,4], 
apoptosis, altered metabolism, and signaling through 
phosphoinositide 3-kinase (PI3K) and Akt[5-7] all con-
tribute to the transition from inflammation to dysplasia.
β-catenin translocation into the nucleus is a 
hallmark of colorectal cancer. Mutations in the genes 
encoding proteins in the phosphatase and tensin 
homolog (PTEN)/PI3K/Akt and Wnt/β-catenin pathways 
lead to colorectal cancer[8-11]. Mutations in adenomatous 
polyposis coli promote dysplasia and cancer by 
reducing β-catenin degradation and enhancing nuclear 
accumulation, detected by immunohistochemical 
staining. Additionally, Akt phosphorylation of β-catenin 
at serine 552 (pβ-cat) increases nuclear translocation 
of pβ-cat, upregulates TCF/LEF transcription, and 
increases in vitro tumor invasion[8]. Data from our 
group showed that mutations in PTEN enhance PI3K/
Akt signaling and pβ-cat levels, leading to increased 
polyp formation[10]. These data suggest that alterations 
in PI3K and β-catenin signaling directly affect stem cell 
activation in dysplasia.
Under conditions of chronic inflammation, cells 
undergo neoplastic transformation after acquiring 
founder mutations. Volgelstein and others coined the 
term “field effect” to reflect the clonal expansion of 
mutated cells that cause areas of dysplasia to appear 
in the vicinity of sentinel areas of sporadic cancer or 
polyps[9,12]. In many cancers, including CAC, clonal 
fields of cells harboring DNA mutations surround 
visible dysplasia or carcinoma. Based on analysis of 
colitis-induced dysplasia, Brentnall and colleagues 
proposed that populations of intestinal epithelial 
cells[13] carrying p53 mutations spread to adjacent 
crypts by migrating over colonic surfaces[14]. Clevers 
and others suggest that the field effect originates in 
mutated intestinal stem cells[15,16]. We hypothesize that 
staining for nuclear pβ-cat provides a useful biomarker 
in identifying such a field effect.
Myo-inositol, a naturally abundant 6-carbon poly-
alcohol isolated from cereals (e.g., rough coat of rice), 
and its derivatives regulate a variety of intracellular 
pathways. Inositol polyphosphates are important as 
second messengers in signal transduction, act as anti-
oxidants, and mediate calcium regulation in membrane 
signaling. Nuclear inositol signaling may also play a role 
in DNA repair and chromatin remodeling[11,17-21]. Due to 
these effects, inositol has been tested in a wide range 
of human clinical trials, including cancer prevention, 
autism, and psychiatric disorders.
Lam et al[22] conducted a dose escalation trial of 
myo-inositol in smokers with bronchodysplasia. They 
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found that myo-inositol (9 g twice a day) reduced 
dysplasia, as well as Akt and phospho-ERK staining in 
dysplastic tissues[23]. Given our previous data linking 
PI3K signaling to β-catenin activation we considered 
the possibility that myo-inositol could reduce dysplasia 
by reducing ISC activation in colitis. However, before 
launching a large scale clinical trial, we wished to 
develop the means for detecting elevated numbers of 
activated ISC in colitis patients using pβ-cat staining. 
Additionally, we wished to determine whether this 
marker would serve as a reliable read-out of ISC 
chemoprevention.
MATERIALS AND METHODS
Animals
C57BL/6 (WT) and C57BL/6 IL-10-/- (IL-10-/-) mice 
were purchased from Jackson Laboratories (Bar Harbor, 
ME, United States). Mice were maintained under specific 
pathogen free conditions at the University of Kentucky. 
All experiments were approved by the University of 
Kentucky IACUC.
Serum myo-inositol measurements
Serum myo-inositol was measured using an enzymatic 
spectrophotometric assay as previously described[24]. 
Briefly, blood was collected by cardiac perfusion 
into untreated 1.5 mL tubes, incubated at room 
temperature for 1 h, centrifuged, and serum was 
collected and stored at -80 ℃. Serum samples were 
treated with glucose oxidase and catalase (Calbiochem, 
San Diego, CA, United States), deproteinized with 
perchloric acid, and subsequently neutralized. Enzymatic 
determination of myo-inositol was done by reading the 
absorbance change at 546 nm from the reduction of 
Fe3+ - to Fe2+ -bathophenanthroline disulphonic acid 
(VWR, Radnor, PA, United States) from the NAD+-
dependent oxidation of myo-inositol by myo-inositol 
dehydrogenase (Sigma, St.Louis, MO, United States). 
Myo-inositol concentration was determined from a 
calibration curve prepared with aqueous standards.
Induction of colitis in mice
Thirteen IL-10-/- mice were divided into three groups: 
control (IL-10-/-), piroxicam-treated (IL-10-/- Px), and 
piroxicam-treated plus myo-inositol (IL-10-/- Px/myo-
inositol). Piroxicam-containing chow was made by 
Harlan-Teklad (Madison, WI, United States). As 
previously described, 8-10 wk old IL-10-/- mice were 
fed chow containing 65 mg/250 g piroxicam for one 
week to synchronize colitis, followed by 85 mg/250 g 
piroxicam to induce colitis[25]. Mice were sacrificed 14 
or 42 d later. For the group treated with myo-inositol, 
mice were treated with 1% (w/v) myo-inositol (Sigma) 
in the drinking water for one week prior to piroxicam 
treatment and for the duration of the experiment. For 
experiments of dextran sodium sulfate (DSS)-induced 
colitis, WT mice were treated with 2% (w/v) DSS (MP 
Biomedical, Santa Ana, CA, United States) for eight 
cycles. A single cycle of DSS consisted of 7 d of DSS 
in the drinking water followed by a recovery period of 
14 d of regular water. Mice were treated with 1% myo-
inositol during the recovery periods.
Disease activity indices
IL-10-/- mice undergoing treatment were scored daily 
or every other day using a standard disease activity 
index (DAI) based on diarrhea, fecal blood (Beckman 
Coulter SENSA Hemoccult Test), and percent weight 
loss as previously described[26]. Each criterion was 
assigned a score from 0 (no diarrhea, fecal blood or 
weight loss) to 4 (severe diarrhea, visible fecal blood, 
and up to 20% weight loss). The daily combined DAI 
score is the sum of each individual criterion.
Histological analysis
Tissues were fixed in 4% neutral buffered formalin 
overnight, processed through paraffin, sectioned at 5 
µm, and stained for hematoxylin and eosin (H&E). For 
murine tissues, colitis scores were calculated based 
on a graded scale of inflammation (0-3), extent (0-3), 
regeneration (0-4), crypt damage (0-4) and percent 
involvement (1-4) as previously described[27]. The 
combined colitis score is the sum of the scores for 
inflammation, extent, and crypt damage/regeneration.
Immunohistochemistry
For human sections, standard of care biopsies were 
processed, stained and analyzed by the pathology 
departments of the University of Chicago or North-
western University. Slides were stained for H&E, 
β-catenin, p53 or Ki67 and staining patterns were 
interpreted by staff pathologists. For laboratory staining 
of anti-pβ-cateninS522 (pβ-cat) and Ki67, paraffin 
sections were rehydrated through graded alcohols and 
antigen retrieval was performed using Target Retrieval 
Solution (Dako, Carpinteria, CA, United States), pH 
6.0, in a decloaking chamber. Sections were incubated 
with anti-pβ-cat (provided by Linheng Li, Stowers) or 
anti-Ki67 (TEC-3, Dako) followed by anti-rabbit or anti-
mouse peroxidase-labeled polymer (Dako). Sections 
were developed using 3,3’-diaminobenzidine (DAB) 
tetrahydrochloride chromagen (Dako) and counter-
stained with hematoxylin.
Cell fractionation
IEC were isolated with EDTA and depleted of CD45 
cells with sheep anti-rat IgG magnetic Dynabeads (Life 
Technologies, Grand Island, NY, United States) preloaded 
with rat anti-mouse CD45 antibody. For subcellular 
fractionation, all buffers contained ProteaseArrest
™ protease inhibitor cocktail (G-Biosciences), and 
phosphatase inhibitor cocktails I and II (Sigma) in 
1:100 dilution. IEC were homogenized in Buffer I (50 
mmol/L Tris-HCl pH 7.4, 100 mmol/L NaCl, 0.01% 
digitonin), lysates were passed through 26G needle, 
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study and again 90 d later. Participants were provided 
a 90 d supply of either maltodextrin (placebo) or myo-
inositol in 9 g packets. Myo-inositol was manufactured 
by Tsuno Rice Fine Chemicals Co., Ltd (Wakayama, 
Japan) and filled into pouches by PharmOps, Inc 
(Phillipsburg, NJ, United States). Myo-inositol and the 
matching placebo were provided by NCI, DCP. For the 
first 14 d, participants dissolved one 9 g single-dose 
packet of study agent in 8 ounces of juice once daily. 
Following this initial period, participants escalated to 
18 g/d taken in divided dose - one 9 g packet in the 
morning and one 9 g packet in the evening for the 
remaining 76 d. Patients were instructed to dose at 
approximately the same time each day, 2 h prior to 
eating. Pre- and post-study biopsies were assessed for 
general histological findings, IHC of p53 and Ki67, and 
patterns of nuclear pβ-cat.
Digital analysis
Slides were scanned using an Aperio ScanScope XT™ 
slide scanner and visualized using ImageScope v11. 
A modified nuclear quantitation algorithm was used 
to identify DAB-positive and DAB-negative epithelial 
nuclei. Slides were assessed for pβ-cat staining using 
the following three criteria; (1) the number of crypts 
containing 2, 3, 4 or 5 pβ-cat-positive cells; (2) the 
number of high powered fields of view containing 3 or 
more crypts, each containing 2 or more pβ-cat-positive 
cells (clustering or “high frequency” fields of view); and 
(3) the number of pβ-cat-positive cells per 100 IEC. 
For analysis of proliferation, numbers of Ki67-positive 
cells per 100 IEC were counted in high frequency fields 
of view as well as adjacent tissue.
Statistical analysis
All pairwise comparisons were made using a Student’s 
t-test; p < 0.05 was considered statistically significant. 
Comparisons among multiple groups were made using 
a one-way ANOVA with post-hoc Tukey’s test.
RESULTS
Treatment with myo-inositol reduces pβ-cat levels in 
murine colitis
Results from prior work indicate that myo-inositol 
inhibits PI3K and ERK signaling as evidenced by reduced 
p-Akt and p-ERK staining in dysplastic tissues[23]. Given 
our previous data linking PI3K signaling to β-catenin 
activation we considered the possibility that myo-inositol 
limits ISC activation in colitis[31]. The effects of myo-
inositol on β-catenin activation were initially examined 
in the IL10-/- and DSS colitis models, which are known 
to progress from inflammation to CAC.
Initially, to establish the relationship between 
dietary intake and serum levels, myo-inositol levels was 
measured in untreated IL-10-/- mice given 1% w/v myo-
inositol in their drinking water. Baseline myo-inositol 
concentrations in IL-10-/- mice were 2.0 ± 0.2 µmol/L, 
then centrifuged at 4 ℃ for 10 min. Pellets were 
resuspended in Buffer II (50 mmol/L Tris-HCl pH 7.4, 
2% Triton X100, 100 mmol/L NaCl) and incubated 
on ice for 30 min, then centrifuged as above. Pellets 
were dissolved in Buffer III (50 mmol/L Tris-HCl pH 
7.4, 0.25% n-Dodecyl-D-maltoside, 100 mmol/L 
NaCl, 2 mmol/L MgCl2) and incubated with 2U of 
Benzonase (Sigma) per 100 µL of lysate for 30 min at 
room temperature. After centrifugation the resulting 
supernatant was used as the nuclear fraction.
Immunoblotting
Proteins were transferred to Immobilon FL (Millipore) 
membrane by semi-dry transfer (Bio-Rad, Hercules, 
CA) and membranes were blocked in Pierce Protein-
free T20 blocking buffer (Thermo, Rockford, IL, 
United States) for 1 h. Primary antibodies for anti-pβ-
cateninS522 (pβ-cat, provided by Linheng Li, Stowers), 
pAktS473 (Cell Signaling, Davers, MA, United States), 
and β-actin (Sigma) were diluted 1:1000 and incubated 
overnight at 4 ℃. HRP-conjugated secondary antibodies 
(KPL, Gaithersburg, MD) were used at 0.02 µg/mL 
and blots were developed using West Pico ECL reagent 
(Thermo, Rockford, IL, United States).
TOPFlash assay
NCM460 cells (normal derived colon mucosa) were 
received by a cell licensing agreement with INCELL 
Corporation (San Antonio, TX, United States), and 
were propagated in M3:10 medium with addition 
of the conditioned medium (30%) from previously 
cultured NCM460 cells. Cells were transfected with 
a reporter construct containing TCF/luc to evaluate 
β-catenin transcription[28]. Transfected cells were 
pre-treated for 3 h with 5 mmol/L myo-inositol and 
overnight with 5 mmol/L myo-inositol or 10 ng/mL 
of TNFα[29,30]. Luciferase was detected with Luciferase 
Reagent (Promega, Madison, WI, United States).
Human sample collection
Colon biopsies were obtained from adult patients 
undergoing diagnostic or surveillance colonoscopy or 
surgical resection at Northwestern University or the 
University of Chicago. For the NCI myo-inositol clinical 
trial, all patients were diagnosed as having colitis-
induced low grade dysplasia (LGD). Informed consent 
was obtained from every patient and samples were 
coded. Collection of all material was approved by 
Northwestern University IRB and sample analysis was 
approved by the University of Kentucky IRB. Some 
biopsies were collected under the NCI Myo-Inositol 
Chemoprevention in Colitis-Associated Dysplasia trial, 
#NWU09-13-02.
NCI clinical trial
Three patients with LGD completed the 90-d clinical 
trial; 1 was given placebo and 2 were given myo-
inositol. Colon biopsies were collected at the start of the 
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while provision of 1% myo-inositol in the drinking water 
raised serum myo-inositol concentrations 2.4-fold, to 
4.9 ± 0.5 µmol/L, p = 0.02. Although our experiments 
were conducted with 1% myo-inositol, we tested the 
effect of 2% myo-inositol as well, and serum levels 
increased to 14.6 ± 1.1 µmol/L (p = 0.01 relative to 
1% myo-inositol). These data document the correlation 
between dietary and serum levels of myo-inositol as 
used in these studies.
Piroxicam (Px) was used to induce colitis in IL-10-/- 
mice, and a cohort of these mice was treated with 1% 
myo-inositol in the drinking water (Figure 1A). While 
no IL-10-/- or IL-10-/- Px/myo-inositol mice died during 
the study, 42% of the IL-10-/- Px mice died during 
the second week of Px treatment (Figure 1B). Myo-
inositol significantly reduced mean diarrhea scores in 
IL-10-/- Px mice from 2.3 ± 0.6 to 0.8 ± 0.3 (p = 0.02), 
and occult fecal blood scores from 2.0 ± 0.4 to 0.9 ± 
0.3 (p = 0.02) (Figure 1C). There was no significant 
change in body weight between myo-inositol-treated 
and untreated mice, though myo-inositol may have 
contributed to increased caloric intake. Composite DAI 
scores were reduced by myo-inositol treatment (Figure 
1C). Given that myo-inositol has anti-inflammatory 
effects[32], we next examined tissue histology in IL-10-/- 
Px and IL-10-/- Px/myo-inositol mice.
Tissue analysis revealed that myo-inositol sig-
nificantly reduced inflammation in colonic tissue from 
IL-10-/- Px mice (Figure 2A and B). Images show 
that myo-inositol normalizes crypt distortion, trans-
mural inflammation, and ulceration induced by Px in 
IL-10-/- mice. These changes correlate with increased 
myeloperoxidase (MPO) staining in IL-10-/- Px mice and 
greatly reduced MPO staining in IL-10-/- Px/myo-inositol 
mice (Figure 2A). This reduction was particularly 
evident near the junction of the proximal and distal 
colon, where IL-10-/- Px mice develop large lymphoid 
aggregates, ulcerated thickened mucosa, and crypt 
distortion. Histological grading of colitis (Methods) 
revealed that myo-inositol reduces inflammation 
scores, the extent of colitis, and composite colitis 
scores (Figure 2B). Inflammation scores were reduced 
Figure 1  Myo-inositol reduces mortality and disease activity indices in IL-10-/- Px mice. A: Schematic diagram of Px and myo-inositol treatment in IL-10-/- mice; 
B: A Kaplan-Meier survival curve shows decreased mortality in IL-10-/- Px/myo-inositol mice; C: Disease activity indices (DAIs) for IL-10-/- Px and IL-10-/- Px/Ins mice. 
For diarrhea and fecal occult blood (FOB), scores are based on a scale from 0-4, with 0 being normal and 4 being the most severe (Methods). Percent weight change 
was calculated as weight change relative to the baseline weight at day 1. The composite DAI includes diarrhea and FOB scores, as well as weight change. The bar 
denotes Px treatment. Data points represent the mean, n = 4 mice in each group. P < 0.05 on day 14.
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in myo-inositol-treated IL-10-/- Px mice from 3.3 ± 1.9 
to 1.0 ± 0.7 (p < 0.05) and myo-inositol completely 
abrogated crypt damage. Treatment with myo-inositol 
reduced the extent of colitis in IL-10-/- Px mice from 2.5 
± 1.2 to 0.5 ± 0.5 (p < 0.05).
pβ-cat staining can be used as a marker of activated 
stem and progenitor cells[25]. Thus, we examined the 
effect of myo-inositol on pβ-cat and pAkt levels in the 
IL-10-/-mice (Figure 3A and B). Results show that myo-
inositol abrogates colitis-induced pβ-cat induction. 
Cell counting revealed that the number of pβ-cat-
positive nuclei dropped by 63% in myo-inositol-
treated IL-10-/- Px mice from 0.3 ± 0.02 to 1.9 ± 0.02 
(p = 0.004). Analysis of the crypt distribution of pβ-
cat demonstrated that in IL-10-/- Px mice there were 
significantly more crypts with > 2 pβ-cat positive nuclei 
in mice with active colitis. By comparison, myo-inositol 
treatment normalized pβ-cat levels in IL-10-/-/Px 
mice (Figure 3B). Similar effects of myo-inositol were 
observed with pAkt staining, in which myo-inositol 
reduced pAkt nuclear staining from 6.4 ± 2.0 to 2.3 ± 
0.7 (p < 0.05) percent. Together these data suggest 
that myo-inositol impairs PI3K and β-catenin activation 
in colitis.
Previously we (GY) found that myo-inositol feeding 
reduced the incidence of cancer in a model of chronic 
DSS colitis[32]. To determine whether myo-inositol 
reduced levels of pβ-cat in these mice, we assessed 
protein levels of pβ-cat in isolated IEC from controls 
and mice treated with eight cycles of DSS with or 
without myo-inositol (Figure 3C). Levels of pAkt 
were assessed to determine if myo-inositol reduces 
this potential activator of b-catenin signaling. WB 
data show that myo-inositol reduced pβ-cat levels by 
59%, from 45 ± 14-fold to 18 ± 4-fold, relative to 
DSS-treated controls (p = 0.04). Nuclear pAkt was 
reduced by 73%, from 11 ± 1-fold to 3 ± 1-fold (p = 
0.006). Together, data from two colitis models indicate 
that oral myo-inositol reduces both pβ-cat and PI3K 
signaling in colitis.
To determine if myo-inositol can reduce infla-
mmation-induced β-catenin activation, we used the 
in vitro TOPFlash assay to assess β-catenin activity 
in response to treatment with TNF and myo-inositol. 
Myo-inositol treatment alone had no discernible effect 
on baseline β-catenin activation. NCM cells treated with 
10 ng/mL TNF showed a 60% increase in β-catenin 
activation (1.00 ± 0.08 vs 1.6 ± 0.12, p < 0.05), 
which was abrogated by co-treatment with 5 mmol/L 
myo-inositol (1.6 ± 0.12 vs 1.13 ± 0.09, p < 0.05; 
Figure 3D). These findings provide evidence that myo-
inositol directly impacts Wnt/β-cat signaling.
Effect of myo-inositol on ISC activation in patients with 
a history of LGD
Several studies, in both human and mice, have shown 
the ability of myo-inositol to reduce dysplasia[23,32]. 
Given the chemopreventive effects of myo-inositol 
on CAC in mice[32] and the inhibition of β-catenin and 
PI3K signaling reported here, we postulated that 
myo-inositol may also reduce ISC activation and CAC 
in patients with longstanding colitis and a history 
Figure 2  Myo-inositol reduces inflammation in IL-10-/- Px mice. A: Representative MPO staining of the proximal-distal junction in IL-10-/- control, IL-10-/- Px 
and IL-10-/- Px/myo-inositol colon at day 28; B: Histological grading of colitis shows that myo-inositol reduces the severity of inflammation, the extent (thickness) of 
inflammation, and the combined colitis score. Untreated IL-10-/- mice did not exhibit inflammation at day 28. Values represent the mean ± SE, n = 4 mice in each 
group.
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of recurrent dysplasia. To examine whether myo-
inositol can be chemopreventive in CAC, we proposed 
a 3 mo trial in which myo-inositol was given to UC 
patients with LGD. We proposed that the frequency 
of pβ-cat-positive IEC would decrease in response to 
dietary myo-inositol treatment. Due to the challenges 
of finding colitis patients with current LGD at the 
time of consent, we were able to enter only five 
patients into the trial. One patient dropped out due to 
adverse events (diarrhea, abdominal pain, flatulence, 
hemorrhoids and increased serum bilirubin), though it 
is not clear that these were study-related. One patient 
had the area of LGD removed with the initial biopsy, 
precluding further analysis at the completion of the 
study. Three patients completed the study; 1 treated 
with placebo and 2 treated with myo-inositol. Statistical 
Figure 3  pβ-cat and pAkt are reduced in colitis mice treated with myo-inositol. A: Representative images of pβ-cat and pAkt staining; B: 
Quantification of the number of pβ-cat- and pAkt-positive nuclei. Distribution of the percent of crypts containing 0-5 pβ-cat-positive nuclei. Values 
represent the mean ± SE, n = 4 mice in each group. aP < 0.05; C: Western blots of IEC showing levels of nuclear pβ-cat and pAkt in the 8 cycle 
model of DSS-induced colitis. Lanes were rearranged to be consistent with formatting. Densitometry was normalized to β-actin and presented 
as the fold change (mean ± SE). n = 2 control mice, 3 DSS-treated mice, and 3 DSS/myo-inositol-treated mice; D: TOPFlash reporter assay 
(shown in relative fluorescence units, RFU) for β-catenin activation in NCM460 cells treated with TNF or myo-inositol. n = 4 separate experiments. 
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analysis of this small study size is not possible. 
However, the results of the staining were used to 
identify a trend of myo-inositol-induced reductions in 
the number of crypts with high numbers of pβ-cat-
positive intestinal epithelial cells.
Data from the myo-inositol-treated patients who 
completed the study did not show reductions in 
established dysplasia (as in Figure 4A and B). However, 
in myo-inositol-treated patients there was a global 
reduction in the percentage of crypts containing two 
or more pβ-cat-positive cells in areas adjacent to 
LGD, which was not observed in the placebo-treated 
patient (Figure 4C). While analyzing the data from 
the 3 patients in the study, we observed “clusters” of 
crypts containing 2 or more pβ-cat-positive cells in non-
dysplastic areas where pβ-cat staining was otherwise 
very sparse (Figure 4C). This aggregation of crypts with 
higher numbers of pβ-cat-positive cells is suggestive 
Bradford EM et al . Myo-inositol reduces β-catenin activation in colitis
Figure 4  Myo-inositol reduces the number of pβ-cat-positive cells in ulcerative colitis patients. A: Representative low power images of biopsies stained for pβ-
cat from a patient before and after 90 d of myo-inositol treatment. B: pβ-cat staining in an area of LGD; C: pβ-cat staining in a non-dysplastic area adjacent to LGD. 
Note the HFC containing multiple pβ-cat-positive nuclei; D: Graphic representation of the percent of crypts from each patient pre- and post-treatment containing 2 or 
more pβ-cat-positive nuclei; E: The percent of all high powered fields of view (FOV) containing HFC in biopsies from each patient. N: Normal tissue; LGD: Low grade 
dysplasia.
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of a field effect, in which foci of activated ISC are 
produced by expansion of mutated cells[14]. In order to 
quantify this effect, we counted the percentage of high 
power fields of view (20X) in which there were at least 
3 crypts containing 2 or more pβ-cat-positive cells, 
henceforth defined as high frequency crypts (HFC). 
In the placebo-treated patient, the percent of HFC at 
day 1 and day 90 was 15% and 19%, respectively. 
However, in the patients treated with myo-inositol, 
the percentages of HFC at day 1 were 36% and 31%, 
which were reduced to 0% and 10%, respectively, by 
day 90 (Figure 4D). Although these findings are far 
from conclusive, they support the notion that myo-
inositol reduces the frequency of activated stem cells in 
patients at high risk for CAC.
Objective assessment of pβ -cat nuclear accumulation in 
colitis
We previously observed that numbers of pβ-cat-
positive IEC are increased in patients within areas of 
colitis-induced LGD and cancer, and inflammation[25]. 
However, the observation of pβ-cat-positive cell 
clustering within non-dysplastic tissue adjacent to 
areas of colitis-induced dysplasia led us to speculate 
that patients with a history of recurrent LGD could 
be stratified based on the presence of HFC. To test 
this hypothesis, a digital algorithm was developed to 
objectively distinguish pβ-cat-positive and negative 
nuclei in human biopsies. This allowed us to more 
accurately compare staining of tissues that were 
processed and stained by a variety of institutions and 
laboratory personnel.
Digital analysis of sections improved the quality of 
data generated by discriminating true positive and true 
negative cells (Figure 5A and B). In some cases, digital 
imaging identified positive cells that were not detected 
by trained observers (Figure 5A, black arrow). In 
other sections, the computer algorithm correctly 
discriminated false positives. The ability to accurately 
identify positive and negative nuclei significantly 
increased the sensitivity of pβ-cat staining.
To test the hypothesis that HFC could be used 
to stratify patients with a history of LGD, biopsies 
from healthy control patients (n = 3), patients with 
a diagnosis of active UC (n = 12), and UC patients 
with a history of LGD (n = 16) were stained for pβ-
cat. In patients with a history of LGD, biopsies were 
taken from histologically normal areas of prior LGD, 
usually near mucosal tattoos marking resected LGD. 
In these tissues, we assessed the number of pβ-cat-
positive cells within individual crypts and portrayed the 
relative distribution of crypts with distinct numbers of 
pβ-cat-positive cells/crypt (e.g., percentage of total 
crypts with 2,3,4 or 5 pβ-cat-positive cells/crypt) 
(Figure 5C). In order to stratify patients, histologically 
normal tissues from areas of previous dysplasia were 
evaluated for HFC (Figure 5D). When we calculated the 
percentage of patients that had at least one HFC, 8.3% 
(1 out of 12) patients with benign, active UC had HFC 
whereas 94% of patients with a history of LGD had at 
least one HFC (15 out of 16). These findings suggest 
that focal increases in pβ-cat staining identify patients 
at risk for dysplasia. If further validated in more 
extensive clinical trials, this biomarker may provide a 
Figure 5  Crypts with elevated pβ-cat staining identify ulcerative colitis 
patients at a high risk for low grade dysplasia. A: Representative images 
of pβ-cat staining and the digital markup in colon biopsies of UC patients with 
normal pβ-cat distribution (benign disease); and B: HFC. Red arrows indicated 
pβ-cat-positive nuclei identified by eye; black arrows indicate false positive or 
negative nuclei properly identified by digital analysis; C: Statistical distribution 
of pβ-cat-positive nuclei in normal biopsies showing that crypts with 2 more 
positive pβ-cat-positive nuclei are rarely detected in healthy patients (diamonds, 
n = 3) or patients with benign, active UC (triangles, n = 12) but are more 
frequent in UC patients with a previous history of LGD (circles, n = 16). Data 
are shown as the percent of crypt cross-sections containing pβ-cat-positive 
nuclei; D: Biopsies from healthy controls, benign UC, and UC patients with a 
history of LGD were analyzed for the presence of HFC. UC: Ulcerative colitis; 
LGD: Low grade dysplasia; HFC: High frequency crypts.
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useful means for testing chemopreventive agents such 
as myo-inositol.
DISCUSSION
The data presented in this study suggest that myo-
inositol is a valuable chemopreventive agent that 
abrogates aberrant activation of ISC during inflamma-
tion and reduces the transition to dysplasia. Additionally, 
these data demonstrate that pβ-cat staining can be 
used to identify HFC within “pre-dysplastic” regions 
in patients with a previous history of colitis-induced 
dysplasia. A central hypothesis addressed in these 
studies was that myo-inositol reduces intestinal 
stem cell activation, detected by reduced nuclear pβ-
cat and pAkt staining. Previous studies indicate that 
inositol compounds have both anti-inflammatory and 
chemopreventive properties[22,23,32-35]. Data here show 
that myo-inositol treatment reduces Akt activation in 
colitis. Additionally, we show that myo-inositol reduces 
β-catenin signaling, a key step in ISC activation. Prior 
data from our group demonstrated that Akt cooperates 
with Wnt to activate β-catenin[25]. In the models tested 
here, it is possible that PI3K inhibition by myo-inositol 
impaired Wnt signaling via reduced β-cat activation.
Because we were interested in early effects of 
myo-inositol during inflammation-induced neoplastic 
transformation, we analyzed data from IL-10-/- mice 14 
d after the induction of colitis, 4 wk before the onset of 
dysplasia. The data presented here demonstrate that 
myo-inositol reduced inflammation, Akt activation, and 
pβ-cat nuclear localization. Additionally, in experiments 
with WT mice on 8 cycles of DSS, analysis of proteins 
from isolated IEC revealed that myo-inositol reduced 
nuclear pβ-cat and pAkt. In the same model, we 
reported that myo-inositol reduced tumor incidence, 
tumor multiplicity, and tumor volume[32]. Based on 
these results we propose that myo-inositol may reduce 
CAC by decreasing the numbers of activated ISC that 
may harbor pro-oncogenic genetic alterations.
5-ASA, a common therapeutic used in the treatment 
of UC, is a potent oxygen radical scavenger and has 
anti-proliferative and pro-apoptotic effects. 5-ASA 
reduces both pAkt and pβ-cat nuclear localization 
in human biopsies and in the IL-10-/- Px model of 
CAC[36,37]. However, in areas of established dysplasia, 
5-ASA did not reduce proliferation or staining for pβ-
cat and pAkt. We propose that like 5-ASA, myo-inositol 
reduces Akt/β-catenin signaling in the early stages of 
dysplastic transformation but not once it is established. 
We posit that 5-ASA and myo-inositol reduce CAC both 
by reducing inflammation-induced Wnt signaling in 
activated ISC at risk for acquiring founder mutations.
To address the question of whether a reduction in 
pβ-cat staining could be a biomarker of “fields” of pre-
dysplastic cells in patients, we analyzed colonic biopsies 
from UC patients with benign disease or a history of 
LGD. We detected more regions with a high frequency 
of pβ-cat -positive nuclei (HFC) in tissue from patients 
with a history of LGD compared to those with benign 
disease. Using the criterion that tissue sections must 
have high powered fields of view with three or more 
crypts containing two or more pβ-cat-positive IEC, 
we were able to distinguish sections from UC patients 
from those who had a history of LGD and those who 
did not. We hypothesize that these data reflect local 
expansions of activated ISC harboring mutations that 
affect Wnt/β-catenin signaling. Inflammation-induced 
carcinogenic genetic and epigenetic changes may 
transmit a survival advantage to select ISC populations. 
Thus, our observations suggest that higher numbers of 
activated ISC may be a biomarker for areas of tissue 
at higher risk for neoplastic transformation. What 
remains unclear is whether myo-inositol primarily 
affects ISC by reducing inflammation, pro-carcinogenic 
inflammatory insults and/or by altering critical ISC 
signaling pathways (e.g., PI3K, Wnt/β-catenin) relevant 
to carcinogenesis. In unpublished studies, we found 
that enhanced nuclear staining of pβ-cat correlates 
highly with increased TCF4/LEF immunoprecipitiation 
and increased expression of downstream TCF4 target 
genes. We propose that reductions of β-catenin activity 
in stem cells by myo-inositol are an essential me-
chanism for its chemopreventive properties. Because 
dysplasia typically arises from expansion of clonal 
stem cells that harbor mutations in key oncogenic 
processes[9,38,39], reducing the numbers of activated 
stem cells in colitis would presumably lower the risk 
for generating neoplastic crypts. Additionally, myo-
inositol is a potent anti-oxidant, and as such it may 
also reduce DNA damage caused by reactive oxygen 
species. We hypothesize that myo-inositol may exert 
chemopreventive properties through both of these 
mechanisms.
In order to test the hypothesis that myo-inositol 
can be used as a chemopreventive in CAC, we propose 
a revised clinical trial. In this trial, UC patients would 
be recruited who have history of recurrent LGD and 
evidence of elevated pβ-cat staining in areas adjacent 
to prior dysplasia. Myo-inositol would be given long-
term (1 year or more) and the primary endpoints 
would include (1) a reduction in the recurrence of LGD; 
and (2) normalized or reduced pβ-cat staining in areas 
proximal to LGD. The primary goal would not be the 
reversal of LGD, but rather the prevention of stem cell 
activation in “high risk” areas of pre-dysplastic fields 
resulting in reduced emergence of new LGD. The 
goal would be to abort the progression to recurrent 
dysplasia in patients who have a history of recurrent 
disease. The clear benefit would be the provision of 
a safe, low cost agent for patients who are found to 
have recurrent LGD during surveillance colonoscopy 
for colitis.
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of dysplasia and colon cancer due to chronic inflammation. Developing a 
biomarker and identifying areas of the colon that harbor the potential for 
neoplastic transformation prior to the onset of histologically-identifiable 
dysplasia is critical for early treatment and cancer prevention. Additionally, there 
is a need for inexpensive, accessible pharmaceuticals to prevent recurrent 
dysplasia and the progression to cancer in IBD patients.
Research frontiers
Colitis-associated cancer (CAC) is a significant concern for patients with 
chronic inflammatory diseases, such as IBD. Although largely preventable 
by stringent surveillance colonoscopy and endoscopic or surgical removal of 
dysplastic tissue, many patients with limited access to health care resources 
remain at high risk for developing cancer. Myo-inositol is a safe, affordable, 
accessible sugar alcohol with limited side-effects and an established history in 
many clinical trials. We posit that myo-inositol is an attractive treatment option 
for patients at high risk for recurrent colonic dysplasia.
Innovations and breakthroughs
This study demonstrated that nuclear staining patterns of Akt-phosphorylated 
β-catenin (pβ-cateninS552) positively correlate with levels of inflammation and 
proliferation in both mouse and human models of intestinal inflammation and 
IBD. Additionally, nuclear staining patterns of pβ-cateninS552 can be used to 
stratify patients with benign colitis and those with a history of dysplasia. In 
mouse models of colitis, oral myo-inositol significantly reduced inflammation 
and numbers of activated stem cells. In a limited clinical trial, myo-inositol 
treatment did not reduce dysplasia, but successfully altered the pattern of pβ-
cateninS552 staining in areas adjacent to dysplasia, suggesting a role for oral 
myo-inositol in limiting stem cell activation during colitis.
Applications
In order to further test the hypothesis that myo-inositol can be used as a 
chemopreventive in CAC, the authors propose a revised clinical trial. In this 
trial, ulcerative colitis patients would be recruited who have history of recurrent 
low grade dysplasia (LGD) and evidence of elevated pβ-cat staining in areas 
adjacent to prior dysplasia. Myo-inositol would be given long-term and primary 
endpoints would include a reduction in the recurrence of LGD and normalization 
of pβ-cat staining in areas proximal to LGD. The primary goal would be the 
prevention of stem cell activation in “high risk” areas of pre-dysplastic fields 
resulting in reduced emergence of new LGD. The clear benefit would be the 
provision of a safe, low cost agent for patients who are found to have recurrent 
LGD during surveillance colonoscopy for colitis.
Terminology
LGD: Mild architectural abnormalities characterized by basally-oriented nuclei, 
mild nuclear enlargement, and nuclear crowding.
Peer-review
This paper describe some important things about: pβ-cateninS552 staining 
faithfully reported the effects of myo-inositol in reducing inflammation and 
intestinal stem cell activation in mice.
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